Mr. Darren Alkins CEO at SPL – Scientific Protein Laboratories, speaks with IPI about their continued development in their science and technical expertise to meet …
Over the past couple of years, how we live our lives and do business have both fundamentally and irrevocably shifted. Richard Ettl at SkyCell explains …
The global drug-device combination products market was estimated to be worth US$ 123.5 billion in 2020 and is forecast to grow at a CAGR of …
The healthcare systems in Southeast Asia are at a critical juncture today. The new wave of COVID-19 infections is straining healthcare facilities as cases continue …
A company’s attitude towards risk fundamentally affects their product development strategy, which can vary between the development of a simple or prototype formulation or a …
Neurological disorders are incredibly complex, and this is reflected in the lack of knowledge of the underlying pathological mechanism for many of these diseases, and …
The global pharmaceutical industry generated more than $1.25tr in revenue in 2019, up from $1.2tr in 2018, and the final figures for 2020 are expected …
To reduce attrition rates in pharmaceutical research and development (R&D), powerful quantitative analytical methods are needed to monitor therapeutic compounds, their metabolites, and target engagement. …
Gene therapy is revolutionising the way we treat human diseases. Any technique that modifies a person’s genes to treat or cure a disease is considered …
When you develop a new therapy, the device you develop or select to deliver will be a key to the overall success of your product. …
IPI was established by professionals with over 30 years of experience in the Pharmaceutical and Life sciences publishing sectors. Peer-Reviewed, Contemporary, Authoritative